Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,576.50 +0.34%
EUR-USD 1.2569 0.1109%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 91.35 +0.54%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Savient Pharmaceuticals Inc

Add to Portfolio

SVNT:US

0.8592 USD 0.0992 13.05%

As of 20:10:00 ET on 05/25/2012.

Snapshot for Savient Pharmaceuticals Inc (SVNT)

Open: 0.7606 Day's Range: 0.7500 - 0.9090 Volume: 1,265,517 Bid: 0.8592
Previous Close: 0.7600 52wk Range: 0.7500 - 8.4900 1-Yr Rtn: -89.50% Ask: 0.8600

Stock Chart for SVNT

No chart data available.
  • SVNT:US 0.8592
  • 1D
  • 1M
  • 1Y
0.7600
Interactive SVNT Chart

Previous Close

Key Statistics for SVNT

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (USD) (ttm) -1.7500
Est. EPS (USD) (12/2012) -1.6970
Est. PEG Ratio -
Market Cap (M USD) 62.20
Shares Outstanding (M) 72.39
Enterprise Value (M USD) (ttm) 108.34
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) -
Price/Sale (ttm) 5.1110
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/03/2012
More SVNT Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for SVNT

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More SVNT Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More SVNT Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More SVNT Cash Flow Data

Company Profile & Key Executives for SVNT

Savient Pharmaceuticals Inc. develops, manufactures, and markets human health care products for niche and wider markets. The Company offers pharmaceutical products for a wide range of medical needs such as weight gain, drugs targeting the control of elevated uric acid levels in the blood, and rheumatology.

Stephen O JaegerChairmanDavid Y NortonInterim Chief Executive Ofcr
David VeitchPresident:EuropeKenneth M BahrtSenior VP/Chief Medical Ofcr
More Company Profile & Key Executives for SVNT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements